Literature DB >> 32621751

Public health insurance and cancer-specific mortality risk among patients with breast cancer: A prospective cohort study in China.

Yuxin Xie1,2, Unnur A Valdimarsdóttir3,4,5, Chengshi Wang2, XiaoRong Zhong1,2, Qiheng Gou1, Hong Zheng1,2, Ling Deng2, Ping He1,2, Kejia Hu2,6, Katja Fall7, Fang Fang6, Rulla M Tamimi8, Ting Luo1,2, Donghao Lu1,2,3,9.   

Abstract

Little is known about how health insurance policies, particularly in developing countries, influence breast cancer prognosis. Here, we examined the association between individual health insurance and breast cancer-specific mortality in China. We included 7436 women diagnosed with invasive breast cancer between 2009 and 2016, at West China Hospital, Sichuan University. The health insurance plan of patient was classified as either urban or rural schemes and was also categorized as reimbursement rate (ie, the covered/total charge) below or above the median. Breast cancer-specific mortality was the primary outcome. Using Cox proportional hazards models, we calculated hazard ratios (HRs) for cancer-specific mortality, contrasting rates among patients with a rural insurance scheme or low reimbursement rate to that of those with an urban insurance scheme or high reimbursement rate, respectively. During a median follow-up of 3.1 years, we identified 326 deaths due to breast cancer. Compared to patients covered by urban insurance schemes, patients covered by rural insurance schemes had a 29% increased cancer-specific mortality (95% CI 0%-65%) after adjusting for demographics, tumor characteristics and treatment modes. Reimbursement rate below the median was associated with a 42% increased rate of cancer-specific mortality (95% CI 11%-82%). Every 10% increase in the reimbursement rate is associated with a 7% (95% CI 2%-12%) reduction in cancer-specific mortality risk, particularly in patients covered by rural insurance schemes (26%, 95% CI 9%-39%). Our findings suggest that underinsured patients face a higher risk of breast cancer-specific mortality in developing countries.
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  breast cancer; cohort study; health insurance; prognosis; survival

Mesh:

Year:  2020        PMID: 32621751     DOI: 10.1002/ijc.33183

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China.

Authors:  Dan Zheng; Linlin Song; Xu Liu; Xiaorong Zhong; Yuxin Xie; Chengshi Wang; Ping He; Xi Yan; Tinglun Tian; Hong Zheng; Ting Luo
Journal:  Gland Surg       Date:  2022-05

2.  Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer.

Authors:  Chuanxu Luo; Shuang Zhao; Cheng Peng; Chengshi Wang; Kejia Hu; Xiaorong Zhong; Ting Luo; Juan Huang; Donghao Lu
Journal:  Br J Cancer       Date:  2022-09-01       Impact factor: 9.075

3.  Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts.

Authors:  Kejia Hu; Chengshi Wang; Chuanxu Luo; Hong Zheng; Huan Song; Jacob Bergstedt; Katja Fall; Ting Luo; Kamila Czene; Unnur A Valdimarsdóttir; Fang Fang; Donghao Lu
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

4.  Financial toxicity and psychological distress in adults with cancer: A treatment-based analysis.

Authors:  Huihui Yu; Hui Li; Tingting Zuo; Li Cao; Xue Bi; Haiyang Xing; Lijuan Cai; Jianmin Sun; Yunyong Liu
Journal:  Asia Pac J Oncol Nurs       Date:  2022-04-20

5.  Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China.

Authors:  Xu Liu; Dan Zheng; Yanqi Wu; Chuanxu Luo; Yu Fan; Xiaorong Zhong; Hong Zheng
Journal:  BMC Cancer       Date:  2021-03-05       Impact factor: 4.430

6.  Development and validation of prognostic nomograms for patients with metastatic small bowel adenocarcinoma: a retrospective cohort study.

Authors:  Hanlong Zhu; Si Zhao; Tianming Zhao; Kang Jiang; Lin Miao; Mingzuo Jiang; Fangyu Wang
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

7.  Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China.

Authors:  Jing Wu; Chengyu Liu; Fengmei Wang
Journal:  Front Public Health       Date:  2021-11-05

8.  Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China.

Authors:  Yuxin Xie; Qiheng Gou; Yingjie Zhang; Keqi Xie; Dan Zheng; Chuanxu Luo; Jiaojiao Suo; Xiaorong Zhong; Ting Luo
Journal:  BMC Cancer       Date:  2022-04-09       Impact factor: 4.430

9.  Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea.

Authors:  Na Liu; Da-Wei Yang; Yan-Xia Wu; Wen-Qiong Xue; Dan-Hua Li; Jiang-Bo Zhang; Yong-Qiao He; Wei-Hua Jia
Journal:  BMC Cancer       Date:  2022-07-29       Impact factor: 4.638

10.  Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.

Authors:  Yanyan Liu; Huining Yi; Kexin Fang; Yuwen Bao; Xin Li
Journal:  Front Public Health       Date:  2022-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.